NCT04440358View on ClinicalTrials.gov

Exablate Blood-Brain Barrier Disruption With Carboplatin for the Treatment of rGBM

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

October 13, 2020

Primary Completion Date

December 31, 2023

Study Completion Date

July 31, 2024

Conditions
Recurrent Glioblastoma
Interventions
DEVICE

Exablate BBBD

BBB opening via Exablate Neuro Type 2 system to deliver carboplatin

DRUG

Carboplatin

Carboplatin infusion on the day of Exablate BBBD procedure to treat cancerous cells in the brain

Trial Locations (3)

20133

Fondazione IRCCS Neurologico Carlo Besta, Milan

M4N 3M5

Sunnybrook Health Sciences Centre, Toronto

120-752

Yonsei University Medical Center, Seoul

Sponsors

Lead Sponsor

InSightec
All Listed Sponsors
lead

InSightec

INDUSTRY

NCT04440358 - Exablate Blood-Brain Barrier Disruption With Carboplatin for the Treatment of rGBM | Biotech Hunter | Biotech Hunter